Deep Blue Medical Advances, Inc. | $5,600,000 | (Apr 22, 2026)
NeoCognition | $40,000,000 | (Apr 22, 2026)
Ideally | $10,000,000 | (Apr 22, 2026)
Certified by Founder
Lodge
Initial Therapeutics
start up
United States
- South San Francisco, California
- 02/05/2023
- Series A
- $75,000,000
Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.
Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
- Industry Biotechnology Research
- Website https://initialtx.com/
- LinkedIn https://www.linkedin.com/company/initial-therapeutics/people/
Monk | $25,000,000 | (Apr 22, 2026)
Reliable Robotics Corporation | $160,000,000 | (Apr 22, 2026)
Humble Robotics | $24,000,000 | (Apr 22, 2026)
Sinai.ai | $1,450,000 | (Apr 22, 2026)
Qualitate | $7,000,000 | (Apr 22, 2026)
Exergy3 Limited | $13,523,900 | (Apr 22, 2026)
Syenta | $26,000,000 | (Apr 22, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
Ultralight | $9,300,000 | (Apr 21, 2026)